Home Buprenorphine Induction: Evaluating a Primary Care Study
This paper critically evaluates Lee, Grossman et al.'s 2008 Journal of General Internal Medicine article examining home buprenorphine/naloxone induction in a New York City primary care setting. The review covers the study's background and significance within the broader opioid dependence treatment landscape, assesses the appropriateness of its literature review, analyzes the methodology used with 103 recruited patients, and examines the reported outcomes — including adverse effects, withdrawal symptoms, and treatment retention at 24 weeks. The paper concludes that the study's data are solid and its findings carry meaningful implications for both medical practice and regulatory policy regarding supervised versus unsupervised buprenorphine induction.
- Introduction and Background: Context of opioid dependence and buprenorphine treatment
- Literature Review: Assessment of cited sources on buprenorphine
- Method: Participant recruitment, design, and data reliability
- Results: Adverse effects, withdrawal rates, and retention outcomes
- Discussion: Policy implications of home induction findings
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The review is tightly focused: it evaluates each section of the source study (background, literature review, method, results, discussion) in a logical, organized sequence rather than offering vague general commentary.
- The author contextualizes the study's significance by grounding it in the broader opioid epidemic and existing regulatory guidelines, giving the reader the background necessary to appreciate why the findings matter.
- Reliability concerns about self-reported data are acknowledged and then resolved with evidence — the author notes that urine testing corroborated patient self-reports, demonstrating critical thinking about research methodology.
Key academic technique demonstrated
This paper demonstrates the technique of structured article critique: each major section of the source study is evaluated in turn using discipline-specific criteria (literature currency, sample composition, data reliability, comparability of outcomes). Rather than simply summarizing the study, the author asks whether methodological choices were justified and whether the conclusions are supported — a hallmark of graduate-level academic analysis.
Structure breakdown
The paper follows the IMRaD structure of the article it reviews: an introduction establishing context and significance, a literature review assessment, a method section evaluating participant recruitment and follow-up design, a results section focusing on adverse effects and retention rates, and a brief discussion linking findings to policy implications. This mirroring approach is a natural and effective choice for an article critique genre.
Introduction and Background
Lee, Grossman et al.'s 2008 Journal of General Internal Medicine article, "Home Buprenorphine/Naloxone Induction in Primary Care," is highly focused: the authors evaluate the success rates of a trial program at a New York City primary care clinic in which eligible patients underwent home buprenorphine induction without medical oversight. The significance of this focus depends upon certain background facts.
Opioid dependence — with manifestations ranging from daily heroin injection to abuse of prescription drugs such as OxyContin — has reached epidemic proportions across large areas of the United States. The difficulty of treating opioid dependence has led to strategies involving medically monitored use of less harmful substitutes, as in the familiar phenomenon of the "methadone clinic." Buprenorphine/naloxone, the partial mu-opioid receptor agonist under study, is a more recently developed substitute that shows tremendous promise: it can be obtained by prescription, allowing the patient to administer it independently, unlike methadone, which requires administration by medical personnel. However, current regulatory guidelines for induction "recommend directly observed initial dosing followed by multiple in-clinic visits during the induction week" (Lee et al., 2008, p. 226). The trial program evaluated in this paper instead implemented home induction: patients were given a prescription and allowed to begin the medication without the heavy supervision that is currently recommended.
Literature Review
The literature review conducted by Lee, Grossman et al. is appropriate. They cite 26 published articles on buprenorphine induction, treatment, and maintenance, including comparisons with methadone, barriers to prescription, and potential complications. Considering that buprenorphine is a relatively new treatment avenue, their literature review is up to date: four cited articles date from the 1990s, and the remainder from 2000 onward. The authors note that "there is little published data specifically examining the feasibility of and early outcomes associated with initiating buprenorphine at home," including adverse effects and retention rates (p. 227). This gap indicates that a study of this kind has the potential to change regulatory guidelines if it can be demonstrated that the currently recommended — though not mandated — heavy supervision for induction may be excessively cautious.
Method
Lee, Grossman et al. conducted a single research study between August 2006 and January 2008 through Bellevue Hospital in New York City. A total of 103 patients eligible for buprenorphine treatment — that is, those with confirmed opioid dependence — were recruited, excluding individuals with "disabling medical or psychiatric conditions" or those on methadone maintenance in excess of 40 mg daily, though others on methadone maintenance were included (p. 227). Opioid dependents were primarily heroin users (68%), followed by prescription opioid abusers (18%) and those on methadone (14%).
Recruited patients were given a prescription for buprenorphine, along with instructions for undergoing induction at home — with an emphasis on doing so while experiencing opioid withdrawal symptoms — and were then asked to telephone the clinic within one to three days of induction. A follow-up visit occurred one week after induction, with subsequent visits scheduled on a case-by-case basis but no less than monthly for several months, then monthly or bi-monthly for the remainder of the study period. The patient population was "predominantly male and racial/ethnic minorities" (p. 228), which reflects the realities of opioid dependence and the population of opioid-dependent patients unlikely to access buprenorphine treatment under the recommended level of supervision.
The nature of the study required self-reporting from recruited patients, which might appear to raise questions about data reliability. However, the fact that 92 patients — 89% of participants — returned for the follow-up visit to provide a report is itself significant (p. 228). Furthermore, self-reported data regarding relapse rates to opioid use, where misreporting might be most likely, were corroborated by urine testing, making any inaccuracies identifiable. The article's Figure 2 presents a graph demonstrating that self-reporting was largely accurate in light of the urine analysis (p. 230).
References
Lee, J. D., Grossman, E., DiRocco, D., & Gourevitch, M. N. (2008). Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine, 24, 226–232. https://doi.org/10.1007/s11606-008-0866-8
Create your account
Always verify citation format against your institution’s current style guide requirements.